Dec 3, 2019 7:00am EST Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Nov 26, 2019 4:05pm EST Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD
Nov 25, 2019 4:05pm EST Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference
Nov 21, 2019 8:00am EST Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
Nov 20, 2019 4:05pm EST Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder
Nov 8, 2019 4:45pm EST Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
Nov 4, 2019 7:00am EST Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting
